Molecular Analysis of Oncogenes and Resistance Mechanisms in Lung Cancer

Launched by UNIVERSITY OF COLORADO, DENVER · Apr 18, 2012

Keywords

ClinConnect Summary

This clinical trial is studying how lung cancer cells respond to specific targeted therapies, which are treatments designed to attack cancer cells by focusing on certain genes. Researchers want to understand why some patients respond well to these therapies while others do not. To do this, they will analyze samples taken from patients' tumors, either from recent procedures or from past biopsies.

The trial is open to adults aged 18 and older who are being treated for lung cancer and may have signs that their cancer is progressing. Participants should be undergoing tests or treatments that involve obtaining tumor samples. If you choose to join the study, you'll be asked to sign a consent form and may undergo procedures to collect tumor tissue. This research could help improve our understanding of lung cancer and potentially lead to better treatment options in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients undergoing investigation or treatment for thoracic cancers with oncogene-targeted therapies
• • 2. Aged 18 years or older
• • 3. Either a) have suspected tumor progression or other condition that dictates a standard-of-care palliative, therapeutic, or diagnostic intervention including but not limited to procedures such as bronchoscopic biopsy, computed tomography (CT) or ultra-sound (US)-guided biopsy, thoracentesis, video assisted thoracoscopic (VATS) pleurodesis, lobectomy, adrenalectomy or pleural catheter placement, providing tumor specimen appropriate molecular analysis or b) have previously had biopsy/surgical intervention with tumor tissue at University of Colorado or an outside institution available for medullar analysis.
• • 4. Patients must have the ability to understand and willingness to sign an informed consent document.
• Exclusion Criteria:
• • -